NeuroSigma

NeuroSigma operates at the intersection of medical devices, digital health, and neuromodulation, with a focused commercial position rather than a broad diagnostics or software portfolio. Its primary differentiator is Monarch eTNS, a prescription, non-invasive system designed for pediatric ADHD and used at home during sleep under caregiver supervision. That gives the company a drug-free treatment proposition and a distinct delivery model compared with conventional pharmaceutical ADHD therapies. The company also maintains a broader pipeline involving epilepsy, depression, PTSD, and other neurologic or psychiatric conditions, although the clearest commercial evidence currently relates to pediatric ADHD. The available peer set does not identify reliable named competitors, so a precise company-to-company comparison is limited. NeuroSigma’s competitive assets instead appear to be its FDA-cleared product, TNS intellectual property, clinical research base, and ability to combine device sales with telehealth and technology licensing. Its small reported workforce of one to ten employees suggests a specialized commercialization model, with manufacturing and channel partnerships playing an important role in market reach.

NeuroSigma’s trajectory shows a transition from long-cycle research and financing toward focused product commercialization. The company was founded in 2008 and accumulated $19.36 million across five funding rounds, including a $11.65 million convertible note in 2016, a $5 million corporate investment from KT Corp in 2021, and a $1 million Venture Round led by Checkmate Capital on Dec 15, 2025. Product activity accelerated in late 2025, when NeuroSigma introduced a second-generation Monarch device following a pilot program and committed $1 million to a high-volume manufacturing line. The next inflection point came in 2026: U.S. commercial launch activity was recorded on Jul 21, 2026, followed by commercial shipments and expanded clinician access through Firefly in September. The company is also extending its platform through telehealth, licensing, and research into epilepsy and neurodevelopmental disorders. Growth remains difficult to quantify because employee data indicates only one to ten people, hiring information is unavailable, and no revenue figures or valuation are disclosed.